title: Reply to 'Safety profile of capecitabine as maintenance treatment after XELOX or FOLFOX in metastatic colorectal cancer patients' by C. Cremolini et al.
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
authors.forename: H Y
authors.initials: HY
authors.lastname: Luo
authors.affiliation: Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China xurh@sysucc.org.cn.
authors.forename: R H
authors.initials: RH
authors.lastname: Xu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D000069287:Capecitabine; D015179:Colorectal Neoplasms; D003841:Deoxycytidine / Q000031:analogs & derivatives; D005472:Fluorouracil / Q000031:analogs & derivatives; D006801:Humans; D002955:Leucovorin; D009944:Organoplatinum Compounds; D010071:Oxaloacetates
chemical_list: D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil